Journal for ImmunoTherapy of Cancer (Nov 2023)
1172 SAIL66, a next generation of T cell engager targeting CLDN6, potentiates efficacy
- Hiroyuki Aburatani,
- Mika Kamata-Sakurai,
- Shinya Ishii,
- Takayuki Kamikawa,
- Naoki Kimura,
- Masaru Muraoka,
- Kenji Taniguchi,
- Ryo Uchikawa,
- Moe Yoshimoto,
- Momoko Okuda-Miura,
- Sho Akai,
- Tatsushi Kodama,
- Hirofumi Sakumoto,
- Shigeto Kawai,
- Mei Shimada,
- Takehisa Kitazawa,
- Tomoyuki Igawa
Affiliations
- Hiroyuki Aburatani
- 5The University of Tokyo, Meguroku, Tokyo, Japan
- Mika Kamata-Sakurai
- Chugai Pharmaceutical Co., Ltd., Kamakura, Japan
- Shinya Ishii
- Department of Medicine for Integrated Approach to Social Inclusion, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
- Takayuki Kamikawa
- 1Chugai Pharmaceutical Co, Ltd., Kamakura, 14, Japan
- Naoki Kimura
- 2Chugai Pharmaceutical Co., Ltd., Yokohama, Kanagawa, Japan
- Masaru Muraoka
- 2Chugai Pharmaceutical Co., Ltd., Yokohama, Kanagawa, Japan
- Kenji Taniguchi
- 2Chugai Pharmaceutical Co., Ltd., Yokohama, Kanagawa, Japan
- Ryo Uchikawa
- 2Chugai Pharmaceutical Co., Ltd., Yokohama, Kanagawa, Japan
- Moe Yoshimoto
- 2Chugai Pharmaceutical Co., Ltd., Yokohama, Kanagawa, Japan
- Momoko Okuda-Miura
- 3Chugai Pharmaceutical Co., Ltd., Kitaku, Tokyo, Japan
- Sho Akai
- 2Chugai Pharmaceutical Co., Ltd., Yokohama, Kanagawa, Japan
- Tatsushi Kodama
- 4Chugai Pharmaceutical Co., Ltd., Chuoku, Tokyo, Japan
- Hirofumi Sakumoto
- 2Chugai Pharmaceutical Co., Ltd., Yokohama, Kanagawa, Japan
- Shigeto Kawai
- 4Chugai Pharmaceutical Co., Ltd., Chuoku, Tokyo, Japan
- Mei Shimada
- 2Chugai Pharmaceutical Co., Ltd., Yokohama, Kanagawa, Japan
- Takehisa Kitazawa
- 2Chugai Pharmaceutical Co., Ltd., Yokohama, Kanagawa, Japan
- Tomoyuki Igawa
- 4Chugai Pharmaceutical Co., Ltd., Chuoku, Tokyo, Japan
- DOI
- https://doi.org/10.1136/jitc-2023-SITC2023.1172
- Journal volume & issue
-
Vol. 11,
no. Suppl 1
Abstract
No abstracts available.
